Bookmarks
Evaluation of de novo diabetes or diabetes worsening in metastatic castration resistant prostate cancer patients treated with abiraterone acetate compared with enzalutamide in England.
Safe People
Organisation name
Astellas Pharma Europe Ltd
Organisation sector
Commercial
Safe Projects
Project ID
CPRD 20_0000234 (ODR2122_2746)
Lay summary
Evaluation of de novo diabetes or diabetes worsening in metastatic castration resistant prostate cancer patients treated with abiraterone acetate compared with enzalutamide in England.
Latest approval date
22/02/2022
Safe Data
Dataset(s) name